The customs broker forwards an email at midnight titled “Notice of FDA Action,” and inside, one word: Detained. Clients react at two extremes — one starts asking what abandonment costs, the other treats it as routine and keeps asking when to pick up the container. Both are wrong. FDA detention is a structured process with response rights and deadlines; where you stand in it, and what evidence you hold, decides whether this shipment releases, gets refused — or drags the whole company onto a red list.
The process: detention is not a verdict
FDA processes imported food along a one-way track:
- Entry review: risk-based screening, possibly document review and sampling
- Detention: FDA finds the goods “appear to” violate — misbranding, suspected contamination, unregistered facility — and issues the notice
- Response window: the notice carries a hearing/response deadline; the importer may submit rebuttal evidence (test reports, corrected documents) or request reconditioning (relabeling, for example)
- Release or Refusal: accepted evidence releases the goods; otherwise Refusal — export or destroy within the deadline
The key phrase is “appears to violate”: at detention, FDA does not need to prove the violation — you need to prove compliance. The response window is not a formality; it is the only part of the process you control.
Five things to do the day the notice lands
- Read the violation code and charge first — labeling, ingredient or sanitation problems have completely different cures
- Lock the response deadline in sight; request extensions early, because missing it is losing by default
- Labeling problems can usually be reconditioned: relabel in the US, pass re-inspection, release — the most survivable category
- Suspected contamination or residues: pull the lot’s third-party test report immediately, or commission a US lab on retained samples
- Arrange storage and cold chain for the waiting period — do not win the process and lose the product
The deep water: Import Alert and DWPE
One detained shipment is a tactical problem; landing on an Import Alert is a strategic disaster. Import Alert is FDA’s red list, and its core instrument is DWPE — Detention Without Physical Examination: one serious violation can list you, after which every shipment is detained automatically on arrival, no examination needed, with the burden of proof reversed — you produce compliance evidence, shipment after shipment. Removal takes a petition backed by a run of clean shipments (five is the commonly cited figure) plus documented corrective action, and FDA review grinds. Do the math: five consecutive shipments, each detained, each evidenced, each awaiting review — that road costs far more than doing the homework before the first container. Which is this article’s real conclusion: staying off the list beats knowing how to get off it, a hundred to one.
Taiwanese products land on the list for the same old reasons: tea residues, seafood drug residues, labeling errors. Labeling is the most unjust of the three because it is entirely preventable — see the seven common US labeling mistakes; and the basic gates whose absence triggers detention outright are covered in the three gates for Taiwanese food exports.
How SKYCARGO takes it from there
SKYCARGO INC holds FDA and USDA agent status and can act as your Importer of Record and consignee — in a detention, we are the party that receives the notice and faces the FDA window. Day to day, we screen labels and documents before shipping so the preventable detention causes stay in Taiwan; when a detention does land, we work the FDA contact, arrange reconditioning or testing, and manage storage and cold chain through the wait — so every day of the response window is spent saving the goods, not finding help. Personal parcels stuck at customs are a Shiptw consolidation question.
Holding a detention notice, or want the risk screened before you ship? Send us the item and the notice and we will reply within one business day.
This article summarizes the FDA import detention and Import Alert framework for reference only. Confirm specifics with current FDA publications and formal advice for individual cases.
